Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Hoosier Oncology Group AstraZeneca |
---|---|
Information provided by: | Hoosier Oncology Group |
ClinicalTrials.gov Identifier: | NCT00613626 |
At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed. It has been noted that patients with increased VEGF levels have a poorer prognosis. Anti-angiogenic agents hold significant promise in the treatment of patients with extensive stage SCLC. ZD6474, a new inhibitor of the VEGFR-2, has shown favorable action in NSCLC.
Condition | Intervention | Phase |
---|---|---|
Small Cell Lung Cancer |
Drug: Cisplatin Drug: Etoposide Drug: Placebo Drug: ZD6474 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver), Parallel Assignment, Efficacy Study |
Official Title: | A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113 |
Estimated Enrollment: | 74 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | February 2010 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Placebo Comparator
Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 matched placebo oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
|
Drug: Cisplatin
Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
Drug: Etoposide
Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
Drug: Placebo
Matched placebo oral daily
|
B: Active Comparator
Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
|
Drug: Cisplatin
Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
Drug: Etoposide
Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
Drug: ZD6474
ZD6474 100mg oral daily to be continued for the duration of the study.
|
OUTLINE: This is a multi-center study.
Arm A:
Cisplatin 60mg/m2 Day 1 + Etoposide 120mg/m2 Day 1,2,3 + Placebo oral daily given continuously for the duration of the study
Arm B:
Cisplatin 60mg/m2 Day 1 + Etoposide 120mg/m2 Day 1,2,3 + ZD6474 100mg oral daily given continuously for the duration of the study
For both arms, PE and toxicity evaluation prior to each cycle and disease assessment by imaging every 2 cycles. Patients with non-PD and acceptable toxicity will continue protocol therapy; patients with progressive disease or excessive toxicity will be taken off treatment. Cycles will be repeated every 21 days up to a total of 4 cycles.
ECOG Performance Status of 0 or 1
Life Expectancy: Not specified
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Nasser Hanna, M.D. | 317.274.3515 | nhanna@iupui.edu |
Contact: Jacob Vinson, M.H.A. | 317-921-2050 | jvinson@iupui.edu |
United States, Indiana | |
Indiana University Simon Cancer Center | Recruiting |
Indianapolis, Indiana, United States, 46202 | |
Contact: Nasser Hanna, M.D. 317-274-3545 nhanna@iupui.edu | |
Contact: Kerry Bridges 317-274-2552 kdbridge@iupui.edu |
Study Chair: | Nasser Hanna, M.D. | Hoosier Oncology Group, Inc. |
Responsible Party: | Hoosier Oncology Group, Inc. ( Nasser Hanna, M.D. ) |
Study ID Numbers: | LUN06-113 |
Study First Received: | January 31, 2008 |
Last Updated: | July 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00613626 |
Health Authority: | United States: Food and Drug Administration |
Extensive Stage Untreated |
Thoracic Neoplasms Carcinoma, Neuroendocrine Etoposide phosphate Carcinoma Neuroendocrine Tumors Carcinoma, Small Cell Neuroectodermal Tumors Cisplatin |
Respiratory Tract Diseases Lung Neoplasms Lung Diseases Neoplasms, Germ Cell and Embryonal Neuroepithelioma Adenocarcinoma Etoposide Neoplasms, Glandular and Epithelial |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Radiation-Sensitizing Agents Antineoplastic Agents |
Therapeutic Uses Physiological Effects of Drugs Neoplasms, Nerve Tissue Antineoplastic Agents, Phytogenic Pharmacologic Actions |